Small-Molecule Targeted Therapy Library Entry

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Tyrosine Kinase Inhibitors (TKIs) DMPK and Bioanalytical Services

TKI bioanalysis is driven by compound-specific disposition rather than one uniform targeted-therapy rule. Many TKIs require CYP3A4 metabolism, P-gp context, microsome / hepatocyte models, and DDI-sensitive interpretation.

Creative Proteomics develops LC-MS/MS workflows for parent-drug quantification, MetID, DDI risk, Phase I / Phase II metabolism, distribution profiling, and custom multi-TKI panel development.

Browse TKI Drug Index Request Custom TKI Method Support

CYP / UGT RoutesSeparate CYP3A4, CYP1A2, and UGT1A9-linked metabolism questions.

DDI and P-gp ContextDistinguish substrate-only TKIs from substrate / inhibitor risk cases.

Panel FlexibilityBuild targeted therapy panels across EGFR, BCR-ABL, and multikinase inhibitors.

TKI Study Logic CYP → P-gp → DDI / Distribution

🧬

CYP-Dominant TKIsMost entries require CYP3A4-aware parent and metabolite interpretation.

↔

P-gp / DDI ContextSelected TKIs require transporter-aware and substrate / inhibitor interpretation.

Ⅱ

Phase II BranchSorafenib and regorafenib add UGT1A9-linked metabolism routes.

📍

Distribution ExceptionAfatinib fits an in vivo distribution route rather than a metabolism-heavy workflow.

Compound-specific TKI workflow design.One page can route parent exposure, MetID, DDI, transporter context, Phase II metabolism, distribution, and multi-TKI panel needs without forcing every compound into the same assay model.

TKI Drug Index

Find the TKI Behind the Study

Use the index to route each TKI to the right analytical question: CYP metabolism, P-gp context, DDI role, Phase I / Phase II MetID, distribution profiling, or custom targeted therapy panel design.

A-Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only TKIs matching all selected values.

12 entries · Page 1 of 4

Analytical Pain Points

What Drives Assay Failure in TKI Studies?

TKI assays fail when every targeted therapy is treated as the same CYP3A4 substrate. This set includes substrate-only TKIs, substrate / inhibitor TKIs, Phase I / Phase II compounds, and a distribution-driven low-metabolism case.

CYP3A4 is common, but not universal

Many TKIs involve CYP3A4, but axitinib adds CYP1A2 and some multikinase inhibitors add UGT1A9-linked Phase II routes.

Our responseCompound-specific enzyme mapping connected to microsome / hepatocyte analysis and MetID.

MetID →

Substrate / inhibitor roles change DDI logic

Imatinib and nilotinib require interpretation beyond parent exposure because DDI risk may involve both substrate and inhibitor roles.

Our responseDDI-aware LC-MS/MS workflows linking parent quantification, enzyme context, and metabolite reporting.

DDI Studies →

P-gp context can alter exposure reading

Several TKIs are P-gp-associated, so exposure shifts may not be explained by metabolism alone.

Our responseIntegrated metabolism / transporter interpretation for selected TKI study designs.

Transporter Context →

Phase I and Phase II should be separated

Sorafenib and regorafenib require Phase I / Phase II-aware interpretation rather than a Phase I-only MetID route.

Our responseWorkflows distinguishing CYP oxidation from UGT1A9-linked metabolism and reporting needs.

Biotransformation →

Distribution-driven TKIs need a different route

Afatinib is best positioned as a distribution-focused, in vivo sample workflow rather than a metabolism-heavy assay.

Our responseParent-drug quantification, in vivo matrix support, and tissue / distribution-oriented method planning.

LC-MS/MS Quantification →

Focused Service Paths

Four Practical Routes for TKI Studies

Select the route according to the compound profile: CYP metabolism, P-gp / DDI risk, Phase I / Phase II metabolism, distribution behavior, or custom multi-TKI panel needs.

Parent TKI Quantification

For parent concentration data across plasma, serum, tissue, cell lysate, in vivo samples, or other biological matrices.

Parent-drug exposure profiling
Plasma / serum bioanalysis
In vivo sample analysis
Matrix-specific LC-MS/MS setup

LC-MS/MS Drug Quantification →

CYP and MetID Workflows

For CYP3A4, CYP1A2, UGT1A9, or metabolite identification questions in TKI studies.

CYP3A4-dominant metabolism
CYP1A2-associated support
Phase I MetID
Parent-to-metabolite interpretation

Metabolite Identification →

DDI, P-gp, and Phase II Interpretation

For transporter context, substrate / inhibitor roles, UGT1A9 metabolism, or exposure-shift questions.

P-gp substrate context
Substrate / inhibitor DDI risk
UGT1A9 Phase II routes
Integrated metabolism / transporter planning

DDI Studies →

Custom TKI Panels

For EGFR TKIs, BCR-ABL TKIs, multikinase inhibitors, matrix comparison, or multi-analyte LC-MS/MS development.

Multi-TKI LC-MS/MS panels
EGFR TKI comparison
Multikinase inhibitor panels
Compound-specific extraction and reporting

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted TKI?

If you are working with a BCR-ABL TKI, EGFR TKI, multikinase inhibitor, P-gp substrate, substrate / inhibitor DDI question, Phase I / Phase II metabolism workflow, distribution-focused compound, or multi-analyte targeted therapy panel, a standard parent-drug LC-MS/MS method may not be enough.

Share your target TKI, matrix, concentration range, CYP pathway, P-gp / transporter concern, DDI role, metabolism focus, distribution objective, MetID requirement, and panel needs.

Target TKI and matrix

Expected concentration range

CYP / UGT pathway focus

P-gp or transporter concern

Substrate / inhibitor DDI role

Panel development needs

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →